Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259612 | 0.88 | LCK (0.66) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL2627659 | 0.88 | LCK (0.51) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL29592816 | 0.88 | LCK (0.66) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL22677549 | 0.84 | ALDH1A1 (0.48) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL2627650 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL10076374 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL6689431 | 0.83 | HSD17B3 (0.62) | KDM4EALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL3339280 | 0.82 | BCHE (0.45) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL15984343 | 0.82 | KDM4E (0.54) | KDM4EALDH1A1LCKHPGDMAPT | |
| SCHEMBL12948863 | 0.82 | KDM4E (0.46) | KDM4EALDH1A1LCKHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | claimed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | claimed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | claimed |
| US-8133902-B2 | Ammosamides as anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110092534-A1 | Ammosamides as Anticancer Agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-04-21 | — | — | US | disclosed |
| WO-2009006319-A2 | AMMOSAMIDES AS ANTICANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080032917-A1 | FLAVIVIRUS PROTEASE SUBSTRATES AND INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2008-02-07 | — | — | US | disclosed |
| WO-2006014232-A2 | DENGUE PROTEASE SUBSTRATES AND INHIBITORS | IRM LLC (BM) | 2006-02-09 | — | — | WO | disclosed |
| US-20050222383-A1 | Prostasin substrates and inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005076886-A2 | PROSTASIN SUBSTRATES AND INHIBITORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | disclosed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | disclosed |
| US-20030059847-A1 | Combinatorial protease substrate libraries | IRM, LLC (BM) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009911-A1 | Hepsin substrates and prodrugs | HPN, SPR, TMPRSS15 | KDM4E 4130/4885ALDH1A1 2407/4885LCK 4125/4885 |
| US-20110092534-A1 | Ammosamides as Anticancer Agents | CCNO, CCNB1, SLC43A1 | KDM4E 1144/4885ALDH1A1 1442/4885LCK 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.